Paper Infomation
Chemotherapy-Related Adverse Reactions in Abdominal Tumors and Clinical Intervention Measures: A Multidisciplinary Analysis
Full Text(PDF, 42KB)
Author: Feng Dai
Abstract: This study constructs a multi-level analytical model and intervention framework for chemotherapy-related adverse reactions in abdominal tumors based on systems biology and complex systems science. By integrating pharmacology, metabolomics, and multidisciplinary collaboration mechanisms, it reveals the cascade pathways of chemotherapeutic toxicity from molecular damage (e.g., DNA fragmentation, oxidative stress) to systemic network dysregulation (e.g., inflammatory cascade reactions, neuroendocrine disturbances). A gene-microbiome interaction model is proposed to explain individual variability, emphasizing the regulatory roles of UGT1A1 polymorphism and gut microbiota diversity in shaping toxic phenotypes. The study establishes an efficiency optimization framework for multidisciplinary collaboration grounded in system dynamics and game theory, highlighting the necessity of multi-target synergy (e.g., combined use of antioxidants and immunomodulators) and dynamic regulation (e.g., real-time monitoring-feedback intervention systems) to transition adverse reaction management toward mechanism-driven precision interventions. Theoretical innovations include the cross-scale coupling model, which integrates hierarchical regulatory logic across molecular-tissue-system levels, and the application of synthetic biology and complex network theory to targeted hepatoprotective drug design and microbial ecological dynamics modeling. These findings provide a theoretical foundation for optimizing chemotherapy safety management and offer an interdisciplinary paradigm for translational medicine research.
Keywords: Abdominal Tumors; Chemotherapy-Related Adverse Reactions; Systems Biology; Multidisciplinary Collaboration; Dynamic Intervention; Gene-Microbiome Interaction; Complex Systems Science
References:
[1] Hegde, P. S., & Byers, L. A. (2017). Targeting the tumor microenvironment in immune checkpoint therapy: Challenges and opportunities. Clinical Cancer Research, 23(8), 1936–1938. https://doi.org/10.1158/1078-0432.CCR-16-2277
[2] Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003). 5-fluorouracil: Mechanisms of action and clinical strategies. Nature Reviews Cancer, 3(5), 330–338. https://doi.org/10.1038/nrc1074
[3] Parman, T., Little, P. F., & Wiley, M. J. (1999). Taxol-induced apoptosis in human SK-N-SH neuroblastoma cells is age-dependent and involves the caspase-9 pathway. Journal of Pharmacology and Experimental Therapeutics, 291(2), 602–610.
[4] Zhang, W., & Innocenti, F. (2019). Pharmacogenomics of EGFR-targeted therapies in colorectal cancer: Gene-drug interactions guiding dose-finding studies. Frontiers in Oncology, 9, 1053. https://doi.org/10.3389/fonc.2019.01053
[5] Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018). Immune-related adverse events associated with immune checkpoint blockade. New England Journal of Medicine, 378(2), 158–168. https://doi.org/10.1056/NEJMra1703481
[6] Rowland, M., Peck, C., & Tucker, G. (2015). Physiologically-based pharmacokinetic modeling in drug development and regulatory science: A workshop report (2013) – Perspectives from the International Society for the Study of Xenobiotics. Drug Metabolism and Disposition, 43(7), 1022–1027. https://doi.org/10.1124/dmd.114.062569
[7] Arany, I., & Safirstein, R. L. (2003). Cisplatin nephrotoxicity. Seminars in Nephrology, 23(5), 460–464. https://doi.org/10.1016/S0270-9295(03)00102-7
[8] Fard, J. K., et al. (2019). Chemotherapy-induced peripheral neuropathy: Mechanisms through genetics, lifestyle, and microbiome. Frontiers in Neuroscience, 13, 1145. https://doi.org/10.3389/fnins.2019.01145
[9] Logan, R. M., et al. (2003). Pathogenesis of oral mucositis. European Journal of Cancer, 39(3), 299–310. https://doi.org/10.1016/S0959-8049(02)00759-2
[10] Ramírez, J., et al. (2018). Pharmacogenomics of taxane disposition: From mechanism to bedside. Expert Review of Clinical Pharmacology, 11(11), 1067–1078. https://doi.org/10.1080/17512433.2018.1526657
[11] Wang, X., et al. (2018). Oxidative stress and mitochondrial apoptosis in chemotherapeutic agent-induced nephrotoxicity. Oxidative Medicine and Cellular Longevity, 2018, 1–11. https://doi.org/10.1155/2018/8365219
[12] Zhou, K., et al. (2020). Gut microbiome and chemotherapeutic-induced toxicity: Mechanisms and management. Critical Reviews in Oncology/Hematology, 154, 103058. https://doi.org/10.1016/j.critrevonc.2020.103058
[13] Innocenti, F., et al. (2011). Comprehensive pharmacogenetic analysis of irinotecan neutropenia in patients with cancer identifies role of DPYD and CES2. Clinical Pharmacology & Therapeutics, 89(3), 470–478. https://doi.org/10.1038/clpt.2010.326
[14] Xiao, W., et al. (2019). Multi-omics integration in toxicology: A promising strategy for predicting drug-induced toxicity. Drug Discovery Today, 24(1), 215–224. https://doi.org/10.1016/j.drudis.2018.09.003
[15] Hesketh, P. J., et al. (2020). Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting: ASCO guideline update. Journal of Clinical Oncology, 38(1), 413–437. https://doi.org/10.1200/JCO.19.02540
[16] Liu, P., et al. (2017). Acupuncture modulates the neuro-endocrine-immune axis in autoimmune diseases. Autoimmunity Reviews, 16(3), 255–265. https://doi.org/10.1016/j.autrev.2017.01.005
[17] Zhang, W., & Innocenti, F. (2019). Pharmacogenomics of EGFR-targeted therapies in colorectal cancer: Gene-drug interactions guiding dose-finding studies. Frontiers in Oncology, 9, 1053. https://doi.org/10.3389/fonc.2019.01053
[18] Forrester, J. W. (1994). System dynamics, systems thinking, and soft OR. System Dynamics Review, 10(2-3), 245–256. https://doi.org/10.1002/sdr.4260100214
[19] Gillies, R. D. (2006). Shapley value and stratified clinical trials. Statistics in Medicine, 25(14), 2418–2437. https://doi.org/10.1002/sim.2409
[20] Himmelstein, D. S., et al. (2017). Systematic integration of biomedical knowledge prioritizes drugs for repurposing. eLife, 6, e26726. https://doi.org/10.7554/eLife.26726
[21] Nash, J. F. (1950). Equilibrium points in n-person games. Proceedings of the National Academy of Sciences, 36(1), 48–49. https://doi.org/10.1073/pnas.36.1.48
[22] Strogatz, S. H. (2001). Exploring complex networks. Nature, 410(6825), 268–276. https://doi.org/10.1038/35065725